Uric Acid Metabolism in Pre-hypertension and the Metabolic Syndrome

被引：28

作者：

Rizzo, Manfredi ^{[1
,2
,3
]}

Obradovic, Milan ^{[4
]}

Labudovic-Borovic, Milica ^{[5
]}

Nikolic, Dragana ^{[1
,4
]}

Montalto, Giuseppe ^{[1
]}

Rizvi, Ali A. ^{[3
]}

Mikhailidis, Dimitri P. ^{[6
]}

Isenovic, Esma R. ^{[4
]}

机构：

[1] Univ Palermo, Biomed Dept Internal Med & Med Specialties, I-90133 Palermo, Italy

[2] Euro Mediterranean Inst Sci & Technol, Palermo, Italy

[3] Univ S Carolina, Sch Med, Div Endocrinol Diabet & Metab, Columbia, SC USA

[4] Univ Belgrade, Inst Vinca, Lab Radiobiol & Mol Genet, Belgrade 11000, Serbia

[5] Univ Belgrade, Fac Med, Inst Histol & Embryol Aleksandar D Kostic, Belgrade 11000, Serbia

[6] UCL, Sch Med, Vascu Dis Prevent Clin, Dept Clin Biochem, London W1N 8AA, England

来源：

CURRENT VASCULAR PHARMACOLOGY | 2014年 / 12卷 / 04期

关键词：

Cardiovascular risk; metabolic syndrome; metabolism; pre-hypertension; uric acid; CORONARY-HEART-DISEASE; SERUM RESISTIN LEVELS; LIPOPROTEIN LDL SUBCLASSES; TYPE-2; DIABETIC-PATIENTS; POST-HOC ANALYSIS; CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; LOW-DENSITY; ARTERY-DISEASE; RISK-FACTOR;

D O I：

10.2174/1570161111999131205160756

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

In humans uric acid (UA) is the end product of degradation of purines. The handling of UA by the renal system is a complex process which is not fully understood. To date, several urate transporters in the renal proximal tubule have been identified. Among them, urate transporter 1 (URAT1) and a glucose transporter 9 (GLUT9) are considered of greater importance, as potential targets for treatment of hyperuricemia and the potential associated cardio-metabolic risk. Therefore, the recognition of the metabolic pathway of UA and elucidation of occurrence of hyperuricemia may provide important insights about the relationship between UA, pre-hypertension (preHT) and the metabolic syndrome (MetS). We also review the available clinical studies in this field, including experimental studies dealing with the mechanisms of UA transport via different transporters, as well as current treatment options for hyperuricemia in patients with MetS, preHT or cardiovascular risk factors.

引用

页码：572 / 585

页数：14

共 50 条

[21] Pre-hypertension: Is it an inflammatory state?
Nandeesha, H.
Bobby, Zachariah
Selvaraj, N.
Rajappa, Medha
[J]. CLINICA CHIMICA ACTA, 2015, 451 : 338 - 342
[22] Pre-Hypertension: Rationale for Pharmacotherapy
Egan, Brent M.
Laken, Marilyn A.
[J]. CURRENT HYPERTENSION REPORTS, 2013, 15 (06) : 669 - 675
[23] Pre-hypertension: another 'pseudodisease'?
Meier, Pascal
Messerli, Franz H.
Baumbach, Andreas
Lansky, Alexandra J.
[J]. BMC MEDICINE, 2013, 11
[24] Pre-Hypertension: Rationale for Pharmacotherapy
Brent M. Egan
Marilyn A. Laken
[J]. Current Hypertension Reports, 2013, 15 : 669 - 675
[25] Should Pre-hypertension Be Treated?
Hiroshi Kanegae
Takamitsu Oikawa
Kazuomi Kario
[J]. Current Hypertension Reports, 2017, 19
[26] Should Pre-hypertension Be Treated?
Kanegae, Hiroshi
Oikawa, Takamitsu
Kario, Kazuomi
[J]. CURRENT HYPERTENSION REPORTS, 2017, 19 (11)
[27] Metabolic syndrome and uric acid nephrolithiasis
Moe, O.
[J]. PEDIATRIC NEPHROLOGY, 2007, 22 (09) : 1418 - 1418
[28] Uric Acid as a Cause of the Metabolic Syndrome
King, Christopher
Lanaspa, Miguel A.
Jensen, Thomas
Tolan, Dean R.
Gabriela Sanchez-Lozada, L.
Johnson, Richard J.
[J]. URIC ACID IN CHRONIC KIDNEY DISEASE, 2018, 192 : 88 - 102
[29] Uric Acid as a Factor in the Metabolic Syndrome
Borges, Rodolfo Leao
Ribeiro, Artur Beltrame
Zanella, Maria Teresa
Batista, Marcelo Costa
[J]. CURRENT HYPERTENSION REPORTS, 2010, 12 (02) : 113 - 119
[30] The uric acid metabolism pathway as a therapeutic target in hyperuricemia related to metabolic syndrome
Colado Simao, Andrea Name
Batisti Lozovoy, Marcell Alysson
Dichi, Isaias
[J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2012, 16 (12) : 1175 - 1187

← 1 2 3 4 5 →